Acute myeloid leukemia (AML) remains a deadly blood cancer, but survival rates are improving, especially in children. Advances in treatment options, including targeted therapies and venetoclax, have led to better outcomes for adult patients. The goal of treatment is to achieve complete remission. Despite progress, there are challenges in treating high-risk cases, such as patients with TP53 mutations. Experts emphasize the importance of genetic testing, personalized treatment approaches, and supportive care. In pediatrics, clinical trials play a crucial role in improving outcomes. Challenges include drug shortages and complications from chemotherapy. Collaborative efforts and ongoing research are key to advancing AML treatment.
Source link
AML: Genetic Testing Unlocks Hope
